Long-Term Correction of Glycogen Storage Disease Type III by AAV-Mediated Gene Therapy Using a Dual Promoter to Express Bacterial Pullulanase

被引：0
|
作者：
Lim, Jeong-A [1 ]
Choi, Su Jin [1 ]
Kishnani, Priya S. [1 ]
Sun, Baodong [1 ]
机构：
[1] Duke Univ, Durham, NC USA
来源：
MOLECULAR THERAPY | 2022年 / 30卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
246
引用
收藏
页码：119 / 120
页数：2
相关论文
共 50 条
  • [31] Letter to the Editors: Concerning "Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia" by Lee et al.
    Brooks, Elizabeth D.
    Kishnani, Priya S.
    Koeberl, Dwight D.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2018, 41 (06) : 913 - 914
  • [32] Short- and long-term outcomes of AAV-mediated TIMP-1 gene therapy in hepatic ischemia and reperfusion injury
    Duarte, S.
    Matian, P.
    Miller, M.
    Busuttil, R. W.
    Coito, A. J.
    TRANSPLANTATION, 2018, 102 : 24 - 24
  • [33] RESCUE AND LONG-TERM OUTCOME OF A MURINE MODEL OF METHYLMALONIC ACIDEMIA FOLLOWING LIVER-DIRECTED, AAV-MEDIATED GENE THERAPY
    Carrillo-Carrasco, Nuria
    Chandler, Randy J.
    Chandrasekaran, Suma
    Venditti, Charles P.
    MOLECULAR GENETICS AND METABOLISM, 2010, 99 (03) : 200 - 200
  • [34] Efficient and Long-Term Correction of Liver Metabolic Diseases by Coupling AAV-Mediated Promoterless Gene Targeting to SaCas9 Nuclease
    De Caneva, Alessia
    Porro, Fabiola
    Bortolussi, Giulia
    Sola, Riccardo
    Lisjak, Michela
    Barzel, Adi
    Giacca, Mauro
    Kay, Mark A.
    Vlahovicek, Kristian
    Zentillin, Lorena
    Muro, Andres F.
    MOLECULAR THERAPY, 2019, 27 (04) : 461 - 461
  • [35] Long-term correction of visual impairment after AAV-NAGLU-mediated gene therapy in a mouse model of mucopolysaccharidosis type IIIB
    Perez, J. A.
    Ribera, A.
    Motas, S.
    Ramirez, L.
    Marco, S.
    Sanchez, V.
    Sanchez, X.
    Bertolin, J.
    Leon, X.
    de la Villa, P.
    Haurigot, V.
    Bosch, F.
    HUMAN GENE THERAPY, 2019, 30 (11) : A157 - A158
  • [36] LONG-TERM CORRECTION OF ARGINASE DEFICIENCY IN A MURINE MODEL USING AAV-BASED GENE THERAPY
    Kosenblatt, R. A.
    Lay, F. D.
    Cederbaum, S. D.
    Grody, W. W.
    Lipshutz, G. S.
    MOLECULAR GENETICS AND METABOLISM, 2009, 98 (1-2) : 143 - 143
  • [37] Long-term, sustained efficacy and safety from a phase 1/2 clinical trial of an AAV8-mediated liver-directed gene therapy in adults with glycogen storage disease type Ia
    Pico, M. L. Couce
    Mitchell, J.
    Ahmad, A.
    Olmos, M.
    Derks, T. G.
    Riba-Wolman, R.
    Weinstein, D. A.
    Rodriguez-Buritica, D. F.
    Lee, C.
    Valayannopoulos, V.
    Crombez, E.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A28 - A28
  • [38] Treatment of aged mice and long-term durability of AAV-mediated gene therapy in two mouse models of Limb girdle muscular dystrophy
    Pozsgai, E.
    Griffin, D.
    Peterson, E.
    Kempton, A.
    Rogers, O.
    Seo, Y.
    Rodino-Klapac, L.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S86 - S87
  • [39] Long-term preservation of retinal function in the rd6 mouse model of retinitis pigmentosa following AAV-mediated gene therapy
    Stupay, Rachel Michelle
    Dinculescu, Astra
    Min, Seok-Hong
    Boye, Sanford L.
    Chiodo, Vince Chiodo
    Hauswirth, William W.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [40] A Novel Small NPC1 Promoter Enhances AAV-Mediated Gene Therapy in Mouse Models of Niemann-Pick Type C Disease
    Hughes, Michael P.
    Nelvagal, Hemanth R.
    Coombe-Tennant, Oliver
    Smith, Dave
    Smith, Claire
    Massaro, Giulia
    Poupon-Bejuit, Laura
    Platt, Frances M.
    Rahim, Ahad A.
    MOLECULAR THERAPY, 2023, 31 (04) : 347 - 347
12345